$ATOS
ATOSSA THERAPEUTICS, INC.

2019 Q1 Form 10-Q Financial Statement

#000143774919009666 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.610M $1.400M
YoY Change 86.43% 20.69%
% of Gross Profit
Research & Development $1.451M $471.0K
YoY Change 208.13% -12.78%
% of Gross Profit
Depreciation & Amortization $13.98K $7.864K
YoY Change 77.81% -80.34%
% of Gross Profit
Operating Expenses $4.064M $1.874M
YoY Change 116.83% 10.26%
Operating Profit -$4.064M -$1.874M
YoY Change 116.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$8.978K $59.00
YoY Change -15316.95%
Pretax Income -$4.073M -$1.874M
YoY Change 117.31% 10.26%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.073M -$1.874M
YoY Change 117.31% 10.26%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$619.5K -$705.7K
COMMON SHARES
Basic Shares Outstanding 9.116M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.60M $4.800M
YoY Change 308.33% 300.0%
Cash & Equivalents $19.57M $4.780M
Short-Term Investments
Other Short-Term Assets $27.96K $600.0K
YoY Change -95.34% 50.0%
Inventory
Prepaid Expenses $835.5K
Receivables
Other Receivables
Total Short-Term Assets $20.78M $5.700M
YoY Change 264.55% 280.0%
LONG-TERM ASSETS
Property, Plant & Equipment $48.21K $100.0K
YoY Change -51.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $17.22K $100.0K
YoY Change -82.78% 0.0%
Total Long-Term Assets $245.2K $300.0K
YoY Change -18.27% -62.5%
TOTAL ASSETS
Total Short-Term Assets $20.78M $5.700M
Total Long-Term Assets $245.2K $300.0K
Total Assets $21.02M $6.000M
YoY Change 250.41% 160.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $464.0K $200.0K
YoY Change 131.99% -50.0%
Accrued Expenses $74.84K $500.0K
YoY Change -85.03% 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.491M $700.0K
YoY Change 113.02% -12.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.491M $700.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.529M $700.0K
YoY Change 118.36% -12.5%
SHAREHOLDERS EQUITY
Retained Earnings -$80.90M
YoY Change
Common Stock $99.70M
YoY Change
Preferred Stock $702.0K
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.50M $5.260M
YoY Change
Total Liabilities & Shareholders Equity $21.02M $6.000M
YoY Change 250.41% 160.87%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$4.073M -$1.874M
YoY Change 117.31% 10.26%
Depreciation, Depletion And Amortization $13.98K $7.864K
YoY Change 77.81% -80.34%
Cash From Operating Activities -$2.149M -$2.387M
YoY Change -9.97% 28.33%
INVESTING ACTIVITIES
Capital Expenditures $51.07K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$51.07K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.34M
YoY Change
NET CHANGE
Cash From Operating Activities -2.149M -2.387M
Cash From Investing Activities -51.07K
Cash From Financing Activities 11.34M
Net Change In Cash 9.188M -2.438M
YoY Change -476.86% 31.07%
FREE CASH FLOW
Cash From Operating Activities -$2.149M -$2.387M
Capital Expenditures $51.07K
Free Cash Flow -$2.149M -$2.438M
YoY Change -11.85% 31.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
2800000
CY2019Q1 atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-280242
CY2018Q1 atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
37595
CY2019Q1 atos Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
3151944
CY2019Q1 atos Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation
AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation
3151944
CY2019Q1 atos Amortization Of Commitment Shares
AmortizationOfCommitmentShares
CY2018Q1 atos Amortization Of Commitment Shares
AmortizationOfCommitmentShares
19852
CY2019Q1 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2019Q1 atos Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
58685
CY2018Q4 atos Prepaid Financial Exchange Fees Current
PrepaidFinancialExchangeFeesCurrent
CY2019Q1 atos Professional Services Current
ProfessionalServicesCurrent
96250
CY2018Q4 atos Professional Services Current
ProfessionalServicesCurrent
110094
CY2019Q1 atos Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
3151944
CY2018Q1 atos Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation
ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
CY2019Q1 atos Research And Development Current
ResearchAndDevelopmentCurrent
392894
CY2018Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
218090
CY2019Q1 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
237856
CY2018Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
518098
CY2019Q1 atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
2800000
CY2019Q1 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
11336710
CY2019Q1 atos Working Capital
WorkingCapital
19300000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
463970
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
353328
CY2019Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
646433
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
697995
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
74844
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
177074
CY2019Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
82706
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
76335
CY2019Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
162619
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
160740
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98056781
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82204902
CY2019Q1 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
701999
CY2018Q4 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
2378997
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
215139
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
275833
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4611845
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90708
CY2019Q1 us-gaap Assets
Assets
21024728
CY2018Q4 us-gaap Assets
Assets
11720446
CY2019Q1 us-gaap Assets Current
AssetsCurrent
20779528
CY2018Q4 us-gaap Assets Current
AssetsCurrent
11549366
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19568247
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4779519
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10380493
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10490493
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7272469
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19678247
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4834519
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9187754
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2437950
CY2019Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18925000
CY2018Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
10052000
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.05
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1070028
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9122171
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5846552
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9122171
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5846552
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
1641979
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1052372
CY2019Q1 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
CY2018Q4 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
1410025
CY2019Q1 us-gaap Deposit Assets
DepositAssets
14218
CY2018Q4 us-gaap Deposit Assets
DepositAssets
16718
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13983
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7864
CY2018Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4073307
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1874382
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.48
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
891758
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
935070
CY2019Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
91667
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
99375
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2613093
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1403465
CY2019Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1741919
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
110642
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-166554
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-102230
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
82508
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-43312
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-428440
CY2019Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2985
CY2018Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-51512
CY2019Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-30076
CY2018Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
7789
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
325635
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
244723
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
44000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
44000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12000
CY2019Q1 us-gaap Liabilities
Liabilities
1528538
CY2018Q4 us-gaap Liabilities
Liabilities
2915436
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21024728
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11720446
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1491141
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2915436
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Atossa Genetics Inc. (the &#x201c;Company&#x201d;) was incorporated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 30, 2009 </div>in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company&#x2019;s fiscal year ends on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31. </div>The Company is focused on development of its pharmaceutical and drug delivery programs.</div></div>
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11336710
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51068
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2148956
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2386882
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4073307
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1874382
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4073307
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1874382
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
4064329
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1874441
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4064329
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1874441
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
12900
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
101000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50706
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37397
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
14600
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
88103
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y255D
CY2019Q1 us-gaap Other Assets Current
OtherAssetsCurrent
27957
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
30942
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9863
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39939
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8978
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
59
CY2019Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
21446
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4355
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
51068
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
702
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2379
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2379
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
702
CY2018Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48212
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54487
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1451236
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
470976
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
2
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
835468
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
509833
CY2019Q1 us-gaap Prepaid Insurance
PrepaidInsurance
234875
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
160576
CY2019Q1 us-gaap Prepaid Rent
PrepaidRent
17100
CY2018Q4 us-gaap Prepaid Rent
PrepaidRent
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11336710
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80904570
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76831263
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
275833
CY2018Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
215139
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
19496190
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8805010
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
6938687
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
5259592
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates:</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div>
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6565514
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
220996

Files In Submission

Name View Source Status
0001437749-19-009666-index-headers.html Edgar Link pending
0001437749-19-009666-index.html Edgar Link pending
0001437749-19-009666.txt Edgar Link pending
0001437749-19-009666-xbrl.zip Edgar Link pending
atos-20190331.xml Edgar Link completed
atos-20190331.xsd Edgar Link pending
atos-20190331_cal.xml Edgar Link unprocessable
atos-20190331_def.xml Edgar Link unprocessable
atos-20190331_lab.xml Edgar Link unprocessable
atos-20190331_pre.xml Edgar Link unprocessable
atos20190331_10q.htm Edgar Link pending
ex_141347.htm Edgar Link pending
ex_141348.htm Edgar Link pending
ex_141349.htm Edgar Link pending
ex_141350.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending